Literature DB >> 10952412

A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors.

A Carr1, A Mullet, Z Mazorra, A M Vázquez, M Alfonso, C Mesa, E Rengifo, R Pérez, L E Fernández.   

Abstract

14F7 murine monoclonal antibody (MAb) is an IgG1 immunoglobulin that is generated by immunizing Balb/c mice with GM3(NeuGc) ganglioside hydrophobically conjugated with human very-low-density lipoproteins and in the presence of Freund's adjuvants. 14F7 MAb binds specifically to GM3(NeuGc), whereas neither N-glycolyl or N-acetyl gangliosides, nor a sulfated glycolipid, are recognized as assessed by enzyme-linked immunosorbent assay or immunostaining on thin layer chromatograms. Immunohistochemical studies in fresh tumor tissues showed that 14F7 MAb strongly recognized in antigen expressed in human breast and melanoma tumors.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10952412     DOI： 10.1089/02724570050109639

Source DB:  PubMed          Journal:  Hybridoma        ISSN： 0272-457X


  34 in total

1.  Induction of leukocyte infiltration at metastatic site mediates the protective effect of NGcGM3-based vaccine.

Authors:  Mayrel Labrada; Isabel Pablos; Francesca Prete; Giselle Hevia; Marilyn Clavell; Federica Benvenuti; Luis E Fernández
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Recombinant AAV-mediated in vivo long-term expression and antitumour activity of an anti-ganglioside GM3(Neu5Gc) antibody.

Authors:  G M Piperno; A López-Requena; A Predonzani; D Dorvignit; M Labrada; L Zentilin; O R Burrone; M Cesco-Gaspere
Journal:  Gene Ther       Date:  2015-07-16       Impact factor: 5.250

3.  Biochemical characterization of prostate-specific membrane antigen from canine prostate carcinoma cells.

Authors:  Lisa Y Wu; Jacqueline M Johnson; Jessica K Simmons; Desiree E Mendes; Jonathan J Geruntho; Tiancheng Liu; Wessel P Dirksen; Thomas J Rosol; William C Davis; Clifford E Berkman
Journal:  Prostate       Date:  2014-01-21       Impact factor: 4.104

4.  A shift from N-glycolyl- to N-acetyl-sialic acid in the GM3 ganglioside impairs tumor development in mouse lymphocytic leukemia cells.

Authors:  Ana Victoria Casadesús; Yuniel Fernández-Marrero; Marilyn Clavell; José Alberto Gómez; Tays Hernández; Ernesto Moreno; Alejandro López-Requena
Journal:  Glycoconj J       Date:  2013-04-02       Impact factor: 2.916

Review 5.  Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions.

Authors:  Yuniel Fernández-Marrero; Alejandro López-Requena
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

Review 6.  Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy.

Authors:  L G Durrant; P Noble; I Spendlove
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

Review 7.  NGcGM3/VSSP vaccine as treatment for melanoma patients.

Authors:  Kirenia Pérez; Marta Osorio; Julio Hernández; Adriana Carr; Luis Enrique Fernández
Journal:  Hum Vaccin Immunother       Date:  2013-02-26       Impact factor: 3.452

8.  Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer.

Authors:  Valeria I Segatori; Ana M Vazquez; Daniel E Gomez; Mariano R Gabri; Daniel F Alonso
Journal:  Front Oncol       Date:  2012-11-08       Impact factor: 6.244

9.  Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines.

Authors:  Mariano R Gabri; Laura L Otero; Daniel E Gomez; Daniel F Alonso
Journal:  J Exp Clin Cancer Res       Date:  2009-12-01

10.  Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer.

Authors:  Hester van Cruijsen; Mariëlle Gallegos Ruiz; Paul van der Valk; Tanja D de Gruijl; Giuseppe Giaccone
Journal:  BMC Cancer       Date:  2009-06-11       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.